Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Alectinib versus crizotinib bij ALK-positief NSCLC
jun 2017 | Longoncologie